메뉴 건너뛰기
The Lancet Oncology
Volumn 16, Issue 1, 2015, Pages 6-7
Blinatumomab: A new era of treatment for adult ALL?
Author keywords

[No Author keywords available]
Indexed keywords

BLINATUMOMAB; CD19 ANTIBODY; CD3 ANTIBODY; CYTOKINE; IMMUNOGLOBULIN; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY;
EID: 84925985383     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71183-0     Document Type: Note
Times cited : (13)
References (7)
  • 1
    • 60949101218 scopus 로고    scopus 로고
    • Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study
    • Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009, 27:911-918.
    • (2009) J Clin Oncol , vol.27 , pp. 911-918
    • Huguet, F.1    Leguay, T.2    Raffoux, E.3
  • 2
    • 57649126380 scopus 로고    scopus 로고
    • Treatment of adult acute lymphoblastic leukemia
    • Gökbuget N, Hoelzer D Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009, 46:64-75.
    • (2009) Semin Hematol , vol.46 , pp. 64-75
    • Gökbuget, N.1    Hoelzer, D.2
  • 3
    • 84865709936 scopus 로고    scopus 로고
    • Adults with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
    • Gökbuget N, Kneba M, Raff T, et al. Adults with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012, 20:1868-1876.
    • (2012) Blood , vol.20 , pp. 1868-1876
    • Gökbuget, N.1    Kneba, M.2    Raff, T.3
  • 4
    • 33846869976 scopus 로고    scopus 로고
    • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL 12/ECOG 2993 study
    • Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL 12/ECOG 2993 study. Blood 2007, 109:944-950.
    • (2007) Blood , vol.109 , pp. 944-950
    • Fielding, A.K.1    Richards, S.M.2    Chopra, R.3
  • 5
    • 84926099033 scopus 로고    scopus 로고
    • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
    • published online Dec 16.
    • Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2014, published online Dec 16. http://dx.doi.org/10.1016/S1470-2045(14)71170-2.
    • (2014) Lancet Oncol
    • Topp, M.S.1    Gökbuget, N.2    Stein, A.S.3
  • 6
    • 0033214207 scopus 로고    scopus 로고
    • Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
    • Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999, 94:2217-2224.
    • (1999) Blood , vol.94 , pp. 2217-2224
    • Winkler, U.1    Jensen, M.2    Manzke, O.3
  • 7
    • 79955662260 scopus 로고    scopus 로고
    • Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
    • Nagorsen D, Baeuerle PA Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011, 317:1255-1260.
    • (2011) Exp Cell Res , vol.317 , pp. 1255-1260
    • Nagorsen, D.1    Baeuerle, P.A.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.